News
September 6, 2023
IGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
Additional Formats
August 3, 2023
IGM Biosciences Announces Second Quarter 2023 Financial Results
Additional Formats
July 3, 2023
IGM Announces Closing of Upsized Public Offering and Concurrent Private Placement and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Additional Formats
June 22, 2023
IGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private Placement
Additional Formats
June 21, 2023
IGM Announces Proposed Public Offering and Concurrent Private Placement
Additional Formats
June 2, 2023
IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development
Additional Formats
June 1, 2023
IGM Biosciences to Present at the Jefferies Healthcare Conference
Additional Formats
May 31, 2023
IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis
Additional Formats
May 30, 2023
IGM Biosciences to Host Conference Call and Webcast to Provide IGM-8444 Clinical Update
Additional Formats
May 12, 2023
IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate Update
Additional Formats
Displaying 1 - 10 of 19